UNSPSC 51273801: Benzocaine/menthol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.

UNSPSC 51273801 Benzocaine/menthol is a Commodity code that in recent state and local procurement shows little alignment with its stated scope. The three most recent opportunities posted under this code—Seminole County's procurement for naloxone and drug deactivation systems, Texas HHS's RFI for direct-to-manufacturer prescription programs, and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products—represent pharmaceutical procurement, pharmacy benefit management, and naloxone distribution rather than benzocaine or menthol products specifically. State and local buyers tagging these solicitations with this code appear to be using it as a catch-all for pharmaceutical and over-the-counter medical supply purchases rather than targeting the benzocaine/menthol commodity itself. The issuing bodies span state health agencies (Texas HHS), regional purchasing cooperatives (MMCAP, administered by Minnesota Department of Administration), and county health departments (Seminole County, Florida).

Activity under this code shows geographic spread across Florida, Texas, and the upper Midwest (Minnesota and participating MMCAP states including Oregon), though the recent solicitations are too few and their scope too divergent from the code's nominal product to establish a clear pattern of genuine benzocaine/menthol procurement. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. MMCAP's RFP (S1070000015802, due March 26, 2026) sought generic multi-source pharmaceuticals and OTC products through authorized wholesalers with awards effective July 1, 2026. The Texas HHS RFI (HHS0017013, posted April 3, 2026) was exploratory market intelligence on direct-to-manufacturer prescription programs with no budget or award value stated. The code shows limited recent state and local activity for benzocaine/menthol as a discrete product line; the opportunities present are pharmaceutical procurement more broadly and do not reflect targeted sourcing of this specific commodity.